Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

PURPOSE: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled re...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra, Violeta, Wang, Anderson T., Castroviejo-Bermejo, Marta, Polanska, Urszula M., Palafox, Marta, Herencia-Ropero, Andrea, Jones, Gemma N., Lai, Zhongwu, Armenia, Joshua, Michopoulos, Filippos, Llop-Guevara, Alba, Brough, Rachel, Gulati, Aditi, Pettitt, Stephen J., Bulusu, Krishna C., Nikkilä, Jenni, Wilson, Zena, Hughes, Adina, Wijnhoven, Paul W.G., Ahmed, Ambar, Bruna, Alejandra, Gris-Oliver, Albert, Guzman, Marta, Rodríguez, Olga, Grueso, Judit, Arribas, Joaquin, Cortés, Javier, Saura, Cristina, Lau, Alan, Critchlow, Susan, Dougherty, Brian, Caldas, Carlos, Mills, Gordon B., Barrett, J. Carl, Forment, Josep V., Cadogan, Elaine, Lord, Christopher J., Cruz, Cristina, Balmaña, Judith, O'Connor, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561606/
https://www.ncbi.nlm.nih.gov/pubmed/35921524
http://dx.doi.org/10.1158/1078-0432.CCR-22-0568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561606/
https://www.ncbi.nlm.nih.gov/pubmed/35921524
http://dx.doi.org/10.1158/1078-0432.CCR-22-0568

Ejemplares similares